부트리시란(Vutrisiran) 시장 규모, 점유율, 성장 분석 : 약물 종류별, 투여 경로별, 환자층별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Global Vutrisiran Market size was valued at USD 496.0 million in 2024 and is poised to grow from USD 558.5 million in 2025 to USD 1443.2 million by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).

The global vutrisiran market is experiencing significant growth, fueled by its innovative RNA interference mechanism that effectively lowers transthyretin protein levels, addressing both hereditary and wild-type ATTR amyloidosis. This therapeutic promise has led to regulatory approvals across key markets and expanded usage to include cardiomyopathy. Enhanced awareness of diagnostic testing, a rising prevalence of the disease, and increased R&D investment further support market expansion. However, challenges persist, including high treatment costs and quarterly administration, which restrict patient access, particularly in lower-income regions. Additionally, stringent payer scrutiny over coverage, underdiagnosis due to low disease awareness, a shortage of specialized clinicians, and limited long-term safety data hinder its acceptance as a first-line therapy, affecting overall market strategies and growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vutrisiran market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vutrisiran Market Segments Analysis

Global Vutrisiran Market is segmented by Drug Class, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Drug Class, the market is segmented into Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside and Other Drug Classes. Based on Route of Administration, the market is segmented into Oral, Injectable and Subcutaneous. Based on Patient Demographics, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vutrisiran Market

A key market driver for the global Vutrisiran market is the increasing prevalence of hereditary transthyretin-mediated amyloidosis (hATTR), a rare and progressive disease causing systemic amyloid deposits that affect multiple organs. As awareness of hATTR grows among healthcare professionals and patients, there is a rising demand for effective therapies, notably Vutrisiran, which offers a novel approach to managing the disease through RNA interference. Additionally, advancements in diagnostic techniques facilitate earlier detection, leading to timely treatment interventions. The growing focus on personalized medicine and improved patient outcomes further propels the interest in Vutrisiran as a transformative therapeutic option.

Restraints in the Global Vutrisiran Market

A significant market restraint for the global Vutrisiran market is the rigorous regulatory approval processes that pharmaceutical products must undergo before reaching the market. These stringent regulations, designed to ensure drug safety and efficacy, can lead to prolonged development timelines and increased costs for manufacturers. Additionally, the complexity of the clinical trials required can pose challenges, particularly for emerging companies with limited resources. This environment may discourage innovation and deter new entrants from pursuing Vutrisiran-related treatments, ultimately hindering market growth and access to this therapeutic option for patients suffering from related conditions.

Market Trends of the Global Vutrisiran Market

The global Vutrisiran market is experiencing significant growth, driven by ongoing advancements in RNAi therapeutics. This trend encompasses enhanced delivery systems, increased potency, and improved safety profiles of RNAi drugs, making them effective options for treating genetic disorders such as hereditary ATTR amyloidosis. As Vutrisiran continues to lead the way in this innovative treatment landscape, increased interest and investment in RNAi technologies are opening pathways for broader applications, establishing a robust pipeline of therapeutic solutions. The convergence of scientific progress and clinical efficacy positions the Vutrisiran market for substantial expansion, reflecting a growing recognition of RNAi as a transformative approach in medicine.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Vutrisiran Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antisense Oligonucleotide
  • Single-Stranded Antisense Oligonucleotides
  • Double-Stranded Antisense Oligonucleotides
• Nucleic Acids
  • DNA-based Nucleic Acids
  • RNA-based Nucleic Acids
• Nucleotide
  • Purine Nucleotides
  • Pyrimidine Nucleotides
• Nucleoside
  • Purine Nucleosides
  • Pyrimidine Nucleosides
• Other Drug Classes

Global Vutrisiran Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Subcutaneous

Global Vutrisiran Market Size by Patient Demographics & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Vutrisiran Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Global Vutrisiran Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blackstone Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medison Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (F. Hoffmann-La Roche Ltd)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (Patheon)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (MSD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Noble Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations